{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:16:50Z","timestamp":1788477410239,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of Fujian Province, China","award":["2019J01458"],"award-info":[{"award-number":["2019J01458"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intrahepatic cholangiocarcinoma (ICC) is a rare but highly aggressive malignant tumor arising within the liver, with a 5-year survival rate of only 20\u201340% after surgery. The role of interleukin-8 (IL-8) in ICC progression remains elusive. A transcriptomic approach based on IL-8 stimulation first revealed significant upregulation of the prometastatic gene CD97 and key epithelial\u2013mesenchymal transition (EMT) factors E-cadherin and vimentin. Immunohistochemistry of 125 ICC tissues confirmed the positive correlation between IL-8 and CD97. Multivariable Cox regression indicated that they are both independent predictors of ICC prognosis. Mechanistically, IL-8 treatment induced CD97 expression at 50 and 100\u00a0ng\/ml in QBC-939 and QBE cells, respectively. Moreover, the induction of cell migration and invasion upon IL-8 treatment was attenuated by CD97 RNA interference, and the expression of EMT-associated genes was dramatically inhibited. To determine whether CXCR1 or CXCR2 are downstream effectors of IL-8, siCXCR2 was applied and shown to significantly attenuate the oncogenic effects of IL-8 by inhibiting the phosphorylation of PI3K\/AKT. Finally, the induction of CD97 expression by the PI3K pathway was verified by treatment with the inhibitor LY294002. In vivo, the significant tumor growth and lung metastasis effects induced by intraperitoneal injection of IL-8 were greatly inhibited by silencing CD97 in nude mice. Collectively, the study presents a novel mechanism of the IL-8-CXCR2-PI3K\/AKT axis in regulating CD97 expression, which leads to ICC metastasis mainly through EMT. The study may provide alternatives for targeting the tumor microenvironment in metastatic ICC.<\/jats:p>","DOI":"10.1038\/s41598-023-45496-3","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T10:02:35Z","timestamp":1698746555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["IL-8 is a novel prometastatic chemokine in intrahepatic cholangiocarcinoma that induces CXCR2-PI3K\/AKT signaling upon CD97 activation"],"prefix":"10.1038","volume":"13","author":[{"given":"Ze-Wu","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ran","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Fei","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"issue":"6","key":"45496_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater, J. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol. 60(6), 1268\u20131289 (2014).","journal-title":"J. Hepatol."},{"issue":"5","key":"45496_CR2","first-page":"1159","volume":"11","author":"HR Shin","year":"2010","unstructured":"Shin, H. R. et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma\u2013focus on East and South-Eastern Asia. Asian Pac. J. Cancer Prev. APJCP 11(5), 1159\u20131166 (2010).","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"20","key":"45496_CR3","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.3390\/cancers13205169","volume":"13","author":"AW Acher","year":"2021","unstructured":"Acher, A. W., Paro, A., Elfadaly, A., Tsilimigras, D. & Pawlik, T. M. Intrahepatic cholangiocarcinoma: A summative review of biomarkers and targeted therapies. Cancers 13(20), 5169 (2021).","journal-title":"Cancers"},{"issue":"4","key":"45496_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.soc.2019.06.002","volume":"28","author":"R El-Diwany","year":"2019","unstructured":"El-Diwany, R., Pawlik, T. M. & Ejaz, A. Intrahepatic cholangiocarcinoma. Surg. Oncol. Clin. N. Am. 28(4), 587\u2013599 (2019).","journal-title":"Surg. Oncol. Clin. N. Am."},{"issue":"2","key":"45496_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/13651820801992641","volume":"10","author":"SA Khan","year":"2008","unstructured":"Khan, S. A., Toledano, M. B. & Taylor-Robinson, S. D. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB Off. J. Int. Hepato Pancreato Biliary Assoc. 10(2), 77\u201382 (2008).","journal-title":"HPB Off. J. Int. Hepato Pancreato Biliary Assoc."},{"issue":"2","key":"45496_CR6","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/jcmm.14848","volume":"24","author":"J Wen","year":"2020","unstructured":"Wen, J. et al. IL-8 promotes cell migration through regulating EMT by activating the Wnt\/beta-catenin pathway in ovarian cancer. J. Cell Mol. Med. 24(2), 1588\u20131598 (2020).","journal-title":"J. Cell Mol. Med."},{"key":"45496_CR7","doi-asserted-by":"publisher","first-page":"152824","DOI":"10.1016\/j.prp.2020.152824","volume":"223","author":"F Deng","year":"2021","unstructured":"Deng, F. et al. Overexpression of IL-8 promotes cell migration via PI3K-Akt signaling pathway and EMT in triple-negative breast cancer. Pathol. Res. Pract. 223, 152824 (2021).","journal-title":"Pathol. Res. Pract."},{"key":"45496_CR8","doi-asserted-by":"publisher","first-page":"111693","DOI":"10.1016\/j.ecoenv.2020.111693","volume":"208","author":"Q Zhou","year":"2021","unstructured":"Zhou, Q. et al. HER2 overexpression triggers the IL-8 to promote arsenic-induced EMT and stem cell-like phenotypes in human bladder epithelial cells. Ecotoxicol. Environ. Saf. 208, 111693 (2021).","journal-title":"Ecotoxicol. Environ. Saf."},{"issue":"16","key":"45496_CR9","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.7150\/jca.29953","volume":"10","author":"J Qu","year":"2019","unstructured":"Qu, J. et al. Mast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8\/Wnt\/beta-catenin pathway. J. Cancer 10(16), 3830\u20133841 (2019).","journal-title":"J. Cancer"},{"issue":"10","key":"45496_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.tibs.2008.07.005","volume":"33","author":"S Yona","year":"2008","unstructured":"Yona, S., Lin, H. H., Siu, W. O., Gordon, S. & Stacey, M. Adhesion-GPCRs: Emerging roles for novel receptors. Trends Biochem. Sci. 33(10), 491\u2013500 (2008).","journal-title":"Trends Biochem. Sci."},{"issue":"2","key":"45496_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3892\/ol.2014.2751","volume":"9","author":"Z He","year":"2015","unstructured":"He, Z., Wu, H., Jiao, Y. & Zheng, J. Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer. Oncol. Let. 9(2), 793\u2013797 (2015).","journal-title":"Oncol. Let."},{"issue":"16","key":"45496_CR12","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.3390\/ijms21165656","volume":"21","author":"C Tanase","year":"2020","unstructured":"Tanase, C. et al. CD36 and CD97 in pancreatic cancer versus other malignancies. Int. J. Mol. Sci. 21(16), 5656 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"45496_CR13","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1002\/hep.30068","volume":"68","author":"Y Yin","year":"2018","unstructured":"Yin, Y. et al. CD97 promotes tumor aggressiveness through the traditional G protein-coupled receptor-mediated signaling in hepatocellular carcinoma. Hepatology 68(5), 1865\u20131878 (2018).","journal-title":"Hepatology"},{"issue":"2","key":"45496_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.neo.2018.12.005","volume":"21","author":"GB Park","year":"2019","unstructured":"Park, G. B. & Kim, D. MicroRNA-503-5p inhibits the CD97-mediated JAK2\/STAT3 pathway in metastatic or paclitaxel-resistant ovarian cancer cells. Neoplasia 21(2), 206\u2013215 (2019).","journal-title":"Neoplasia"},{"issue":"5","key":"45496_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1309\/A6AB-VF3F-7M88-C0EJ","volume":"118","author":"G Aust","year":"2002","unstructured":"Aust, G. et al. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am. J. Clin. Pathol. 118(5), 699\u2013707 (2002).","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"45496_CR16","doi-asserted-by":"publisher","first-page":"101042831769431","DOI":"10.1177\/1010428317694319","volume":"39","author":"ZW Meng","year":"2017","unstructured":"Meng, Z. W., Liu, M. C., Hong, H. J., Du, Q. & Chen, Y. L. Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 39(3), 1010428317694319 (2017).","journal-title":"Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med."},{"issue":"3","key":"45496_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-013-2698-4","volume":"141","author":"S Yao","year":"2013","unstructured":"Yao, S. et al. Genetic variants in microRNAs and breast cancer risk in African American and European American women. Breast Cancer Res. Treat. 141(3), 447\u2013459 (2013).","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"45496_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/1541-7786.MCR-07-0032","volume":"5","author":"CF MacManus","year":"2007","unstructured":"MacManus, C. F. et al. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol. Cancer Res. MCR 5(7), 737\u2013748 (2007).","journal-title":"Mol. Cancer Res. MCR"},{"issue":"7","key":"45496_CR19","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/carcin\/bgs181","volume":"33","author":"XJ Li","year":"2012","unstructured":"Li, X. J. et al. As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling. Carcinogenesis 33(7), 1302\u20131309 (2012).","journal-title":"Carcinogenesis"},{"issue":"40","key":"45496_CR20","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1038\/onc.2014.441","volume":"34","author":"C Visciano","year":"2015","unstructured":"Visciano, C. et al. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. Oncogene 34(40), 5175\u20135186 (2015).","journal-title":"Oncogene"},{"issue":"5","key":"45496_CR21","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0002-9440(10)64443-4","volume":"161","author":"M Steinert","year":"2002","unstructured":"Steinert, M. et al. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am. J. Pathol. 161(5), 1657\u20131667 (2002).","journal-title":"Am. J. Pathol."},{"issue":"1","key":"45496_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"45496_CR23","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28(11), 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"issue":"D1","key":"45496_CR24","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51(D1), D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"45496_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139(5), 871\u2013890 (2009).","journal-title":"Cell"},{"issue":"2","key":"45496_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2015.09.008","volume":"379","author":"H Zhang","year":"2016","unstructured":"Zhang, H., Yang, T., Wu, M. & Shen, F. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 379(2), 198\u2013205 (2016).","journal-title":"Cancer Lett."},{"key":"45496_CR27","doi-asserted-by":"crossref","unstructured":"Zeng, D., Wu, J., Luo, H., Li, Y., Xiao, J., Peng, J., Ye, Z., Zhou, R., Yu, Y., Wang, G., Huang, N., Wu, J., Rong, X., Sun, L., Sun, H., Qiu, W., Xue, Y., Bin, J., Liao, Y., Li, N., Shi, M., Kim, K. M. & Liao, W. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J. Immunother. Cancer 9(8) (2021).","DOI":"10.1136\/jitc-2021-002467"},{"issue":"1","key":"45496_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13073-020-00741-6","volume":"12","author":"HW Lee","year":"2020","unstructured":"Lee, H. W. et al. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 12(1), 47 (2020).","journal-title":"Genome Med."},{"issue":"Suppl","key":"45496_CR29","first-page":"115","volume":"13","author":"A Techasen","year":"2012","unstructured":"Techasen, A. et al. Cytokines released from activated human macrophages induce epithelial mesenchymal transition markers of cholangiocarcinoma cells. Asian Pac. J. Cancer Prev. 13(Suppl), 115\u2013118 (2012).","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"45496_CR30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s13046-019-1396-4","volume":"38","author":"Y Fu","year":"2019","unstructured":"Fu, Y., Liu, S., Zeng, S. & Shen, H. From bench to bed: The tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 38(1), 396 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"45496_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.canlet.2015.07.009","volume":"367","author":"MH Mannino","year":"2015","unstructured":"Mannino, M. H. et al. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 367(2), 103\u2013107 (2015).","journal-title":"Cancer Lett."},{"issue":"9","key":"45496_CR32","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.4049\/jimmunol.1800141","volume":"201","author":"Q Li","year":"2018","unstructured":"Li, Q., Anderson, C. D. & Egilmez, N. K. Inhaled IL-10 suppresses lung tumorigenesis via abrogation of inflammatory macrophage-Th17 cell axis. J. Immunol. 201(9), 2842\u20132850 (2018).","journal-title":"J. Immunol."},{"issue":"3","key":"45496_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-13-0214","volume":"2","author":"M Oft","year":"2014","unstructured":"Oft, M. IL-10: Master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol. Res. 2(3), 194\u2013199 (2014).","journal-title":"Cancer Immunol. Res."},{"issue":"17","key":"45496_CR34","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1158\/0008-5472.CAN-17-2268","volume":"78","author":"TA Karakasheva","year":"2018","unstructured":"Karakasheva, T. A. et al. IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment. Cancer Res. 78(17), 4957\u20134970 (2018).","journal-title":"Cancer Res."},{"issue":"7","key":"45496_CR35","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/gutjnl-2019-319200","volume":"69","author":"C Heichler","year":"2020","unstructured":"Heichler, C. et al. STAT3 activation through IL-6\/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut 69(7), 1269\u20131282 (2020).","journal-title":"Gut"},{"issue":"1","key":"45496_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/ijo.2015.3234","volume":"48","author":"X Long","year":"2016","unstructured":"Long, X. et al. IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways (Review). Int. J. Oncol. 48(1), 5\u201312 (2016).","journal-title":"Int. J. Oncol."},{"issue":"2","key":"45496_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3892\/ijo.2014.2761","volume":"46","author":"XT Fu","year":"2015","unstructured":"Fu, X. T. et al. Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2\/STAT3\/Snail pathway. Int. J. Oncol. 46(2), 587\u2013596 (2015).","journal-title":"Int. J. Oncol."},{"issue":"4","key":"45496_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3324\/haematol.11606","volume":"93","author":"M van Pel","year":"2008","unstructured":"van Pel, M., Hagoort, H., Kwakkenbos, M. J., Hamann, J. & Fibbe, W. E. Differential role of CD97 in interleukin-8-induced and granulocyte-colony stimulating factor-induced hematopoietic stem and progenitor cell mobilization. Haematologica 93(4), 601\u2013604 (2008).","journal-title":"Haematologica"},{"issue":"2","key":"45496_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000521613","volume":"11","author":"I Lurje","year":"2022","unstructured":"Lurje, I. et al. Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma. Liver Cancer 11(2), 162\u2013173 (2022).","journal-title":"Liver Cancer"},{"issue":"4","key":"45496_CR40","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.surg.2013.12.037","volume":"155","author":"H Sueoka","year":"2014","unstructured":"Sueoka, H. et al. Blockage of CXCR2 suppresses tumor growth of intrahepatic cholangiocellular carcinoma. Surgery 155(4), 640\u2013649 (2014).","journal-title":"Surgery"},{"issue":"4","key":"45496_CR41","doi-asserted-by":"publisher","first-page":"e0266027","DOI":"10.1371\/journal.pone.0266027","volume":"17","author":"Y Yamamoto","year":"2022","unstructured":"Yamamoto, Y. et al. CXCR2 signaling might have a tumor-suppressive role in patients with cholangiocarcinoma. PLoS One 17(4), e0266027 (2022).","journal-title":"PLoS One"}],"updated-by":[{"DOI":"10.1038\/s41598-024-58952-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45496-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45496-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45496-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T11:05:20Z","timestamp":1712833520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45496-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["45496"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-45496-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]},"assertion":[{"value":"6 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18711"}}